Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss ...
The FDA banned the use of red dye No. 3 in foods and medicines sold in the U.S. because it has been shown to cause cancer in ...
The U.S. Food and Drug Administration hopes "front-of-package" labeling will better improve the American population's health, ...
A non-opioid painkiller from Vertex Pharmaceuticals could become a blockbuster, but questions remain on whether it will prove ...
Averaging up to 20% of weight loss, adults taking Tirzepatide had at least 25 fewer breathing interruptions each hour as they ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
Stallergenes Greer, a biopharmaceutical company specialising in allergen immunotherapy (AIT), announces that the European Commission (EC) has approved the extension of indication of Palforzia® ...
This may start to bring down the cost of brand-name competitors—here's who might get access, and one major difference from ...
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
The drug has been specifically approved for adults with moderate-to-severe obstructive sleep apnea and obesity. Its use is recommended alongside increased exercise and a lower-calorie diet. Over the ...
For many people, the end of the year is a mad rush to wrap things up before the holidays, and so it was for the FDA. Notable regulatory decisions include the first drug approval for a prevalent ...
The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...